Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687921 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL13498450 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL19240726 | 0.95 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL19240725 | 0.95 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL19240724 | 0.95 | ALDH1A1 (0.49) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL15080935 | 0.89 | ALDH1A1 (0.41) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL15726987 | 0.89 | ALDH1A1 (0.41) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL1687958 | 0.89 | ALDH1A1 (0.41) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL25200465 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 | |
| SCHEMBL22296232 | 0.85 | ALDH1A1 (0.43) | ALDH1A1LMNAHPGDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | PFIZER INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3414234-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| EP-3426637-B1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ANGEL PHARMACEUTICAL CO LTD (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021252339-A1 | SUBSTITUTED PURINE-2,6-DIONE COMPOUNDS AS KRAS INHIBITORS | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | SHENZHEN TARGETRX, INC. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11155546-B2 | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2021-10-26 | — | — | US | disclosed |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3851438-A1 | BTK INHIBITOR, PHARMACEUTICALLY ACCEPTABLE SALT, POLYMORPH AND APPLICATION THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen TargetRx. Inc. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3715346-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | Dana-Farber Cancer Institute (US) | 2020-09-30 | — | — | EP | disclosed |
| US-8552010-B2 | Inhibitors of Bruton'S tyrosine kinase | PHARMACYCLICS, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8497277-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8476284-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2012170976-A2 | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | MERCK PATENT GMBH (DE) | 2012-12-13 | — | — | WO | disclosed |
| EP-2526933-A2 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2526934-A2 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2526771-A1 | Inhibitors of bruton's tyrosine kinase | Pharmacyclics, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | LCK, BTK, BRAF | ALDH1A1 3535/4885LMNA 4628/4885HPGD 2000/4885 |
| US-20100249092-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885LMNA 2409/4885HPGD 1580/4885 |
| US-11111242-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | JAK2, JAK3, JAK1 | ALDH1A1 1079/4885LMNA 4103/4885HPGD 1336/4885 |
| US-11155546-B2 | 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof | CYP2D6, DPYD, TPMT | ALDH1A1 312/4885LMNA 3203/4885HPGD 379/4885 |
| US-20230009153-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYRROLO[2,3-D]PYRIDINYL ACRYLAMIDES | JAK2, JAK3, JAK1 | ALDH1A1 1206/4885LMNA 4515/4885HPGD 800/4885 |
| US-20130065899-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885LMNA 2409/4885HPGD 1580/4885 |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | LCK, BTK, LYN | ALDH1A1 4246/4885LMNA 4105/4885HPGD 3246/4885 |
| US-20120101113-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | ALDH1A1 4117/4885LMNA 2541/4885HPGD 3546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.